Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
about
Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsChronic VEGF blockade worsens glomerular injury in the remnant kidney modelAntineoplastic agents and thrombotic microangiopathy.Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature.Renal involvement in preeclampsia: similarities to VEGF ablation therapyClinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective studyVEGF inhibition, hypertension, and renal toxicityNew insights into molecular mechanisms of diabetic kidney disease.Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients.Development of nephrotic syndrome after administration of sorafenib in a case of metastatic renal cell carcinoma.Sunitinib induced nephrotic syndrome and thrombotic microangiopathy.The use of sunitinib in renal cell carcinoma: where are we now?Guidelines for treatment of renal injury during cancer chemotherapy 2016.Morphological spectrum of renal pathology and its correlation to clinical features in patients with disseminated intravascular coagulation: a study involving a series of 21 autopsy cases.All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.Hypertension in malignancy-an underappreciated problem.Collapsing Glomerulopathy and Thrombotic Microangiopathy in Postpartum Period: Two Case Reports.Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case reportA Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
P2860
Q28080163-B629A721-69D7-4151-A5BB-D104CDDF48FEQ28728129-B174362C-7C03-42E4-A1AD-59BD67B9E199Q30251919-638D6BCA-D9D9-4B11-8F45-F1E55A98ED50Q33418425-635C0921-A760-4A9A-8C6E-6CA479AFA73BQ34735646-9AD2A1E2-F4E2-445F-939B-E17F03972425Q36546814-7735E204-5ED6-4D3E-A10A-E364C25F16B5Q37103555-B1094602-DAAA-49B1-9C52-370C0F6FA52FQ37598306-61663598-BE49-456B-9A62-F0FB3503A957Q37928188-A35464DB-625F-40AA-9B95-0CE3FEE07C2DQ37946895-A1D9C825-B156-49A3-95A1-F1273CC103C5Q39712982-8A872236-FC0A-4B98-9D45-016EC7872F24Q48634468-CD424016-632E-4AA5-9DC7-DE7BFA33F8CAQ50063006-D544C1B0-837D-45AE-8E41-62E00AAD715CQ53025906-8322455A-36B7-45DC-927D-AF6F82EDE9BCQ54494865-A743A978-5FC8-4367-843F-6B5290819EAAQ55071881-9C5AB4BB-D4F4-4385-9BBB-CDCE900AB1B5Q55331086-B2B0150E-D33D-43B3-B212-929E8EBDC3EDQ57809492-6B894184-7B27-4E24-B2BE-D8DA4BF1DB3AQ58584938-2B2568C3-4D43-41D1-9E96-135E8CDBCF06
P2860
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@ast
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@en
type
label
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@ast
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@en
prefLabel
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@ast
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@en
P2093
P356
P1476
Inhibition of tyrosine kinases ...... to thrombotic microangiopathy.
@en
P2093
Jorge Martinez-Ara
Mari Luz Picazo
Olga Costero
Pilar Zamora
Rafael Selgas
Sara Romero
P304
P356
10.1093/NDT/GFP666
P407
P577
2009-12-16T00:00:00Z